Background: The PRAETORIAN trial (A Prospective, Randomized Comparison of
Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) showed …

Background There is limited evidence guiding the selection between subcutaneous and
transvenous implantable cardioverter-defibrillators (ICDs) in patients with arrhythmogenic …

Within the last decade, implantable cardioverter‐defibrillator (ICD) systems with non‐
transvenous leads were developed in order to minimize complications related to the …

Purpose Low-field magnetic resonance imaging (MRI), ie MRI with a static magnetic field
strength< 0.5 T, has been reported to be safe in patients with pacemakers, however there …

Background Programming implantable cardioverter-defibrillators (ICDs) with a high-rate
therapy strategy has proven to be effective in reducing shocks and is associated with a …

Abstract The Arrhythmia Working Group of the Austrian Society of Cardiology (ÖKG) has set
the goal of systematically structuring and organizing the acute care of patients with …

We also found no effect on thrombin or fibrin generation, either immediately following aspirin
therapy or after withdrawal. Importantly, we found no effect on fibrinolysis, which would have …

The use of implantable cardiac devices has increased in the last 30 years being a dynamic
field and an interesting challenge. The evolution of devices in serious cardiac rhythm …

The use of implantable cardiac devices has increased in the last 30 years. The evolution of
devices in serious cardiac rhythm pathology management has led progressively to the …

A 36-year-old man had a markedly dilated left ventricle, an ejection fraction of 20%, and a
diagnosis of noncompaction of the ventricular myocardium [1–22]. In 2004 he had received …